Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Integrated Dose Counter on an Albuterol Hydrofluoroalkane (HFA) Metered Dose Inhaler (MDI)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent/assent~* General good health~* Asthma or COPD~* Capable of understanding the requirements, risks, and benefits of study participation.~* Able to demonstrate proper metered-dose inhaler use and technique.~* Other inclusion criteria apply~Exclusion Criteria:~* History of life-threatening asthma or COPD that is defined for this protocol as an asthma or COPD episode that required intubation and/or was associated with hypercapnia, respiratory arrest or hypoxic seizures.~* Culture-documented or suspected bacterial or viral infection of the upper or lower respiratory tract, sinus, or middle ear that is not resolved within 2 weeks of Screening Visit.~* Is being treated with a long-acting β2-agonist alone.~* Is currently being treated with Ventolin HFA.~* Any asthma or COPD exacerbation requiring oral corticosteroids within 2 months of Screening Visit. A subject must not have had any hospitalization for asthma or COPD within 4 months prior to Screening Visit.~* Historical or current evidence of a clinically significant non-asthmatic acute or chronic condition.~* Uncontrolled hypertension~* History of any adverse reaction to any component of the HFA-MDI formulation.~* Participation in any investigational drug study within the 30 days preceding the Screening Visit.~* Other exclusion criteria apply.

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Albuterol MDI (Type: None): All participants in this study will receive an albuterol MDI inhaler.

Based on this trial design, predict the completion outcome and termination type (if applicable).